Jennifer Litton, MD, associate professor in the Department of Breast Medical Oncology at The University of Texas MD Anderson Cancer Center, discusses her opinion on the use of PARP inhibitors in the field of breast cancer.
Jennifer Litton, MD, associate professor in the Department of Breast Medical Oncology at The University of Texas MD Anderson Cancer Center, discusses her opinion on the use of PARP inhibitors in the field of breast cancer.
Recent research has led to the availability of numerous drugs for the treatment of HER2+ breast cancer, while PARP inhibitors are only the first targeted therapy for triple-negative breast cancer to meet a primary endpoint. These will be tested in a variety of combinations in the future, Litton predicts.
PARP inhibitors are currently only being used in cases of metastatic breast cancer with aBRCAgermline mutation. But, Litton notes, we cannot forget about ER+ breast cancer as well, even though there are only a small percent of these patients with aBRCAgermline mutation.
Batalini Explores Role of UGT1A1 in Patients Treated With Sacituzumab Govitecan for HR+ MBC
April 22nd 2024During a Community Case Forum live event in partnership with The Arizona Clinical Oncology Society, Felipe Batalini, MD, discussed the TROPiCS-02 trial of sacituzumab govitecan and the impact of the UGT1A1 status on adverse event frequency.
Read More
Breast Cancer Leans into the Decade of Antibody-Drug Conjugates, Experts Discuss
September 25th 2020In season 1, episode 3 of Targeted Talks, the importance of precision medicine in breast cancer, and how that vitally differs in community oncology compared with academic settings, is the topic of discussion.
Listen